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17BETA-ESTRADIOL-INDUCED UP-REGULATION OF TYPE II COLLAGEN
EXPRESSION IS MEDIATED BY ER ALPHA/SP/SOX-9/P300 COMPLEX
THROUGH COL2A1 PROMOTER/FIRST INTRON INTERACTIONS IN
DIFFERENTIATED AND DEDIFFERENTIATED ARTICULAR CHONDROCYTES
L. Maneix1, N. Boujrad2, G. Flouriot2, M. Demoor1, K. Boumediene1,
S. Moslemi1, P. Galera1
1Lab. of Extracellular Matrix and Pathology, Caen, France; 2Lab. of Molecular
Endocrinology of Reproduction, CNRS UMR 6026, Rennes, France
Purpose: Type II collagen, encoded by COL2A1 gene, is a phenotypic
marker of articular cartilage whose expression is strongly decreased during
osteoarthritis (OA) process. Speciﬁc proteins (Sp) and Sox proteins have
been previously characterized to be major regulators of this gene. Besides,
the existence of a link between estrogen deprivation and osteoarthritis
in postmenopausal women suggests that 17β-estradiol (17β-E2) may be a
critical modulator of cartilaginous matrix homeostasis. The aim of present
study was to investigate the molecular mechanisms regulating type II
collagen gene expression under the effect of 17β-E2, and to characterize the
genomic pathway via estrogen receptors (ER).
Methods: Articular chondrocytes were isolated from 3-week old rabbits
and incubated for 24 hours with increasing concentrations of 17β-E2 (0 to
10 nM). Nuclear proteins were extracted and submitted to gel retardation
assays in order to determine Sp and Sox proteins binding activities on
COL2A1 gene. In some experiments, relative expression of Sp1/Sp3 or Sox-9
was inhibited by siRNAs strategies. Moreover, chromatin immunoprecipi-
tation was used to study protein-protein interactions on COL2A1 promoter
and enhancer sequences.
Results: We have previously shown that 17β-E2 could stimulate type II
collagen neosynthesis, protein level and corresponding steady-state levels
of COL2A1 mRNAs in primary and in vitro dedifferentiated rabbit artic-
ular chondrocytes. 17β-E2 action was mediated, in part, by an ERα/Sp
transactivating effect on the -266/-63 bp region of COL2A1 proximal pro-
moter. Our new data showed that 17β-E2 also increases the DNA-binding
activities of Sp1/Sp3 and Soxs proteins to the ﬁrst intron region including
COL2A1 speciﬁc enhancer. In addition, Sp1, Sp3 and Sox-9 siRNAs prevented
hERα66-induced transactivation of COL2A1, suggesting that these factors
are required for COL2A1 up-regulation. Moreover, chromatin immunopre-
cipitation assays indicated that ERα physically interacts in vivo with Sp1,
Sp3, Sox-9 and p300 transcription factors, on both COL2A1 promoter and
enhancer sequences. Thus, considering that all these transcription factors
are known to act in concert, we proposed that 17β-E2 in vivo effect
could be mediated by a bridging complex, composed of ERα, Sp1, Sp3,
Sox-9 and p300 transcription factors, which could establish a physical link
between the two main cisregulatory regions of the gene, and consequently,
may facilitate COL2A1 transcription process. Besides, this transcriptional
activation of COL2A1 gene requires the ERα transactivation domains, AF-1
and AF-2, as demonstrated by using ERα mutants lacking these functional
domains.
Conclusions: Understanding the molecular basis for 17β-E2/ERα induction
of COL2A1 transcription provides new insights into molecular mechanisms
of OA and could be therefore attractive for some applications in the tissue
engineering of cartilage.
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IN VITROMODEL FOR CALCITONIN AS A COMBINATION THERAPY FOR
OSTEOARTHRITIS
N. Mehta, J. Gilligan
Unigene Lab. Inc., Fairﬁeld, NJ
Purpose: The study was designed to ﬁnd synergistic effects of salmon
calcitonin (sCT) with reference treatments for (osteo)arthrits in the bovine
cartilage explant model in which degradation is induced by a cocktail of
three cytokines.
Methods: Matrix degradation was quantiﬁed by measuring proteoglycan
release, collagen release and MMP activity. The pro-inﬂammatory molecule
PGE2 was also measured.
In the ﬁrst experiment maximum ineffective concentrations of sCT,
Galardin, Celebrex, Dexamethasone, BB-94 and Doxycyclin were deter-
mined. In the second experiment, combinations of sCT with each of the
other drugs were assayed to determine if there was a statistically signiﬁcant
synergistic effect of the combination
Results: Calcitonin (0.5 nM) and Doxycyclin (10 μM) alone had a no effect
on collagen release. They change the collagen release from 135 to 133 and
125 ng CTX-II per mg cartilage respectively. The combination, however,
decreased the collagen release to 73 ng CTX-II per mg cartilage. This effect
is stronger then expected based on the effects of
the compounds alone and is therefore synergistic.
A similar effect is observed for the combination of Calcitonin (0.5 nM) with
BB-94 (10 nM). Alone they change the collagen release from 135 to 133
and 137 ng CTX-II per mg cartilage respectively, while the combination
reduced the collagen release to 88 ng CTX-II per mg cartilage.
Although no synergy of sCT with the other compounds was detected in
this study, further experiments to determine a more appropriate range of
concentrations of each of the compounds needs to be carried out.
Conclusions: The combination of sCT with with doxycyclin and BB-94
can act synergistically to reduce type II collagen degradation in a bovine
cartilage explant model. These results lend support to the concept that a
combination therapy to reduce matrix degradation in OA can be developed
with very low doses of each of the compounds. Such a combination
therapy has the potential to alleviate the safety concerns with high doses
of doxycyclin or BB-94.
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HEALTHY MINDS, HEALTHY JOINTS: DEFINING A NOVEL ROLE FOR BACE1
IN CARTILAGE EROSION
M. Tortorella1 , A. Tomasselli2, L. Song2, R. TenBrink2, C. Anglin2,
A.-M. Malfait3
1Guangzhou Inst. of Biomedicine and Hlth., Guangzhou, China; 2Pﬁzer, St.
Louis, MO; 3Rush Med., Chicago, IL
Purpose: The role of aspartyl proteases in osteoarthritis has been rela-
tively unexplored. BACE-1 is an aspartic-acid protease important in the
pathogenesis of Alzheimer’s disease and in the formation of myelin sheaths
in peripheral nerve cells. BACE-1 is currently a target for therapeutic
intervention in neural degenerative diseases and the goal of these studies
was to explore its role in cartilage metabolism.
Methods: Selective small molecule inhibitors of BACE-1 were tested for
their ability to block cartilage breakdown in various pre-clinical assays.
Results: In these studies selective inhibition of BACE with various small
molecules blocked the cytokine induced glycosaminoglycan release in
both bovine and human cartilage explant cultures. Furthermore, immuno-
staining of human OA cartilage sections showed that BACE-1 protein was
localized in areas of cartilage undergoing matrix breakdown and ﬁbrillation.
Gene expression proﬁling suggested that the effect of BACE inhibition is
partly through the regulation of MMP13 message. Finally, BACE-1 null mice
are currently being analyzed for resistance to cartilage erosion in a surgical
instability model of OA.
Conclusions: These ﬁndings identify a novel role for BACE-1 in carti-
lage breakdown, raising the possibility that BACE-1 inhibitors will act as
therapeutics not only in Alzheimer’s, but in arthritic diseases as well.
268
LAMA4 IS EXPRESSED BY CLUSTERS OF HYPERTROPHIC CHONDROCYTES
IN OSTEOARTHRITIC CARTILAGE AND REGULATED BY EPIGENETIC
MECHANIMS
F.C. Fuerst1, M.H. Stradner1, G. Gruber2, H. Angerer1, G. Hofmann1,
M. Kremser1, D. Setznagel1, A. Leithner2, W.B. Graninger1
1Med. Univ. Graz, Graz, Austria; 2Univ. Clinic for Orthopedic Surgery, Graz,
Austria
Purpose: Hypertrophic chondrocytes release proteinases resulting in a loss
of extracellular matrix compounds in osteoarthritis (OA. In the search
for molecular mechanisms leading to chondrocyte hypertrophy epigenetic
events have been discussed. In a genome-wide methylation analysis we
identiﬁed a consistent hypomethylation of the gene coding for the integrine
LAMA4 in OA chondrocytes
Methods: We obtained 15 samples of human osteoarthritis cartilage
during total knee joint replacement. Immunohistochemistry for LAMA4
was performed after histological grading for OA according to the OARSI
score. Isolated chondrocytes were cultured in the presence of 5-AZA-
deoxy-cytidine and expression of LAMA4 was quantiﬁed using the Taqman
Realtime PCR Assay.
